Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl L Hansen

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2014
Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applicationsColin Walsh, Kevin Ou, Nathan M Belliveau, et al.
Genome Research|October 14, 2008
In-depth characterization of the microRNA transcriptome in a leukemia progression modelFlorian Kuchenbauer, Ryan D Morin, Bob Argiropoulos, et al.
Nature Methods|May 24, 2011
High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arraysVéronique Lecault, Michael Vaninsberghe, Sanja Sekulovic, et al.
Haematologica|December 9, 2017
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemiaEdith Schneider, Anna Staffas, Linda Röhner, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2014
Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applicationsColin Walsh, Kevin Ou, Nathan M Belliveau, et al.
Genome Research|October 14, 2008
In-depth characterization of the microRNA transcriptome in a leukemia progression modelFlorian Kuchenbauer, Ryan D Morin, Bob Argiropoulos, et al.
Nature Methods|May 24, 2011
High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arraysVéronique Lecault, Michael Vaninsberghe, Sanja Sekulovic, et al.
Haematologica|December 9, 2017
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemiaEdith Schneider, Anna Staffas, Linda Röhner, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2020
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infectionBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Science Translational Medicine|April 6, 2021
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primatesBryan E Jones, Patricia L Brown-Augsburger, Kizzmekia S Corbett, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Pageof 4